The Cooper Companies, Inc. · NASDAQ:COO

The Cooper Companies — Cooper Companies — Investor Presentation (November 2007)

35 slides from The Cooper Companies's investor presentation, Nov 14, 2007

  1. Slide 1: Exhibit 99.1

    Exhibit 99.1 NYSE: COO

  2. Slide 2: Forward-Looking Statements

    11/13/2007 2 This presentation contains forward-looking projections of Cooper’s results. Actual results could differ materially from these projections. Additional information concerning factors that could cause material differences can be found in Cooper’s periodic filings with the Securities and Ex

  3. Slide 3: The Company

    11/13/2007 3 Medical devices Vision care Women’s healthcare Market leadership Favorable demographics Consistent long-term performance THE COMPANY

  4. Slide 4: Consistent Performance

    11/13/2007 4 17% 26% 30% 2001- 2006 5 Year CGR EPS - Continuing Operations Operating Income Revenue CONSISTENT PERFORMANCE (CAGR Ex Call Outs)

  5. Slide 5: COO Business Goals

    11/13/2007 5 Low to mid-teens revenue growth for next five years CVI double digit CSI high-teens, including M&A Earnings growth mid-teens to high- teens COO BUSINESS GOALS

  6. Slide 6: COO Business Goals: CooperVision

    11/13/2007 6 CooperVision Grow 1.5 times worldwide market next 5 years Largest specialty lens company Move to #2 position worldwide Operating margin mid to upper 20’s COO BUSINESS GOALS

  7. Slide 7: COO Business Goals: CooperSurgical

    11/13/2007 7 CooperSurgical Revenue of $300M by 2011 including acquisitions Operating margin in mid 20’s COO BUSINESS GOALS

  8. Slide 8: CooperVision

    11/13/2007 8 CooperVision 11/13/2007

  9. Slide 9: Market Segments

    11/13/2007 9 (worldwide, millions of $’s) 4% 8% $2,555 $1,718 $2,082 $1,191 All Other Spheres Specialty 7% $6,778 $4,732 Total Market Daily Disposable Spheres 11% $2,505 $1,459 CGR 2011 2006 MARKET SEGMENTS

  10. Slide 10: Geographic Market Segments

    11/13/2007 10 7% $6,778 $4,732 Total Market *Includes Mideast and Africa Source: company reported data and independent market audit Asia/Pacific Europe* Americas (millions of $’s) 12% $2,555 $1,440 3% $1,559 $1,328 6% $2,665 $1,964 CGR 2011 2006 GEOGRAPHIC MARKET SEGMENTS

  11. Slide 11: World Market Drivers

    11/13/2007 11 Growing indication: myopia Favorable demographics: teens Specialty and value-added vs. commodity: improved lens technology Geographic expansion WORLD MARKET DRIVERS

  12. Slide 12: CooperVision Today

    11/13/2007 12 $800M in 2007 vs. $38M in 1994 #2 in Europe; #2 in US; #3 worldwide Specialty lenses Worldwide toric lens market leader COOPERVISION TODAY

  13. Slide 13: Contact Lens Global Market: Market Share

    11/13/2007 13 % change and % *Independent audit data +5 +5 +6 +5 Total +5 +6 +6 +6 Specialty -2 n/c -2 n/c Reusable Sphere +29 +12 +31 +10 Single Use CVI YTD07 CVI Q307 Contact Lens Global Market* share

  14. Slide 14: Contact Lens Global Market: US versus ROW

    11/13/2007 14 US versus ROW *Independent audit data 100% +5 Total 33% (n/c) +3 Specialty 57% (-2) +2 Reusable Sphere 10% (+2) +2 Single Use %US YTD07 Contact Lens Global Market* 100% +5 22% (+1) +8 33% (-3) -2 45% (+2) +10 %ROW YTD07

  15. Slide 15: Contact Lens Global Market by Region

    11/13/2007 15 % change *Independent audit data +5 +5 +6 +5 Total +21 +10 +21 +10 Asia +4 n/c +4 +1 Europe +2 +5 +6 +4 United States CVI YTD07 CVI Q307 Contact Lens Global Market*

  16. Slide 16: Contact Lens Global Market: Q307 versus Q207

    11/13/2007 16 Q307 versus Q207 *Independent audit data +5 +n/c Total +5 +4 Asia n/c n/c Europe +7 -2 United States CVI MKT Contact Lens Global Market*

  17. Slide 17: Contact Lens Global Market: Competitive Landscape

    11/13/2007 17 % change *Independent audit data +5 +5 Total (100%) -5 -11 Others (40%) +5 +6 COO (17%) +15 +14 JNJ (43%) YTD Q3 Contact Lens Global Market* Competitive Landscape

  18. Slide 18: Revenue Guidance

    11/13/2007 18 *as issued on 9/6/07 $940 - $967 TOTAL $150 - $157 CSI $790 - $810 CVI 2007* Revenue Guidance ($Millions ) $1,020 - $1,090 $165 - $170 $855 - $920 2008

  19. Slide 19: Updates

    11/13/2007 19 • Manufacturing capacity • New Products – 2 week silicone hydrogel – Silicone hydrogel toric – Proclear daily disposable in Japan UPDATES

  20. Slide 20: Women's Healthcare

    11/13/2007 20 Keeping you at the forefront of women’s healthcare™ WOMEN’S HEALTHCARE

  21. Slide 21: Women's Healthcare

    11/13/2007 21 Favorable demographics Pharma, capital equipment, in-office Fragmented market Changing market dynamics WOMEN’S HEALTHCARE

  22. Slide 22: CooperSurgical Strategy

    11/13/2007 22 Consolidate market New in-office product opportunities Fertility and hospital procedures Disposable/reusable components COOPERSURGICAL STRATEGY

  23. Slide 23: Procedures

    11/13/2007 23 Cervical disease Incontinence Infertility Osteoporosis (diagnostic) Menstrual disorders Menopause Birth control PROCEDURES

  24. Slide 24: CooperSurgical Today

    11/13/2007 24 $125M FY 2006 Consumables 85%; capital equipment 15% In-office market segment leader Recent acquisitions U.S. 85% COOPERSURGICAL TODAY

  25. Slide 25: CSI Objectives

    11/13/2007 25 $125M 2006 – $300M 2011 25% operating margin Expand in hospital segment 20% ROI M&A hurdle Accelerate organic growth Expand geographically CSI OBJECTIVES

  26. Slide 26: Financial Highlights

    11/13/2007 26 NYSE:COO Financial Highlights

  27. Slide 27: Capital Structure 7-31-07

    11/13/2007 27 Total Debt $861 Stockholders’ Equity $1435 Total Capitalization $2297 Total Debt /Capitalization 38% CAPITAL STRUCTURE 7-31-07 ($’s in Millions)

  28. Slide 28: COO Consolidated Revenue

    11/13/2007 28 $244 $330 $389 $698 $734 $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 2002 2003 2004 2005 2006 ($ in millions) $315 $412 CVI CSI $490 $807 $859 COO CONSOLIDATED REVENUE $71 $82 $101 $109 $125

  29. Slide 29: Consolidated Operating Income

    11/13/2007 29 $189 $95 $67 $117 $175 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 0% 5% 10% 15% 20% 25% ($ in millions) Operating Income Operating Margin CONSOLIDATED OPERATING INCOME (Ex Call Outs)

  30. Slide 30: CVI Consolidated Operating Income

    11/13/2007 30 $60 $89 $107 $171 $186 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 0% 10% 20% 30% ($ in millions) Operating Income Operating Margin CVI CONSOLIDATED OPERATING INCOME (Ex Call Outs)

  31. Slide 31: CSI Consolidated Operating Income

    11/13/2007 31 $20 $21 $18 $14 $24 $0 $5 $10 $15 $20 $25 2002 2003 2004 2005 2006 0% 5% 10% 15% 20% 25% ($ in millions) Operating Income Operating Margin CSI CONSOLIDATED OPERATING INCOME (Ex Call Outs)

  32. Slide 32: Taxes

    11/13/2007 32 Net Operating Loss Carryforwards $143 million Global Tax Arrangement Effective Tax Rates TAXES

  33. Slide 33: Cash Flow from Operating Activities

    11/13/2007 33 $56 $80 $101 $184 $151 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 ($ in millions) CASH FLOW FROM OPERATING ACTIVITIES

  34. Slide 34: History of Successful Deleveraging

    11/13/2007 34 8% 38% 27% 20% 21% 34% 31% 23% 36% 35% 0% 10% 20% 30% 40% DEBT/CAP HISTORY OF SUCCESSFUL DELEVERAGING Jan.’05 – Acquired Ocular Sciences Feb.’02 – Acquired Biocompatibles Dec.’97 – Acquired Aspect Vision Nov.’06 – Acquired Lone Star Nov.’05 – Acquired Inlet & NeoSurg

  35. Slide 35: Goper

    Goper Goper

Cooper Companies — Investor Presentation (November 2007) on 6ix